What is Calafiore Cardioplegia?
Calafiore cardioplegia is a warm blood cardioplegia technique that uses intermittent administration of a blood-to-crystalloid mixture (typically 4:1 ratio of blood to crystalloid) to induce and maintain cardiac arrest during cardiac surgery. This method was developed as a myocardial protection strategy during cardiopulmonary bypass (CPB) to protect the heart from ischemic damage while providing a bloodless operative field 1.
Key Characteristics
Composition and Delivery:
- Blood-to-crystalloid ratio: 4 parts blood to 1 part crystalloid solution 1
- Temperature: Administered warm (normothermic, around 36°C) rather than cold 2
- Administration pattern: Given intermittently, typically every 20 minutes during aortic cross-clamping 3
- Potassium concentration: Contains high potassium (8-20 mEq/L) to induce depolarized cardiac arrest 1
Route of Administration:
- Primarily delivered antegrade into the aortic root at 60-100 mmHg pressure 1
- Can be supplemented with retrograde delivery via coronary sinus in complex cases 1
- May include direct perfusion through completed vein grafts for enhanced protection 4
Clinical Performance
Advantages Over Alternatives:
The evidence strongly supports Calafiore's effectiveness:
Superior to Del Nido: Recent experimental data shows Calafiore provides better myocardial protection than Del Nido cardioplegia, with faster functional recovery (72% vs 40% of baseline left ventricular developed pressure at 30 minutes reperfusion, p<0.001) and lower troponin I levels 5
Lower delirium rates: Compared to HTK (Bretschneider) crystalloid cardioplegia, Calafiore was associated with significantly lower delirium rates on postoperative day 3 (3.0% vs 12.0%, p=0.024) and shorter ICU stays 6
Reduced vasoplegic syndrome: Use of warm blood cardioplegia (Calafiore) appears safer than cold crystalloid cardioplegia, with lower rates of vasoplegic syndrome development 7
Warm vs Cold Calafiore: When comparing temperature variations of the same technique, warm Calafiore shows slight advantages over cold administration, with better left ventricular developed pressure recovery (97% vs 68% of baseline) and less cellular edema on electron microscopy 2.
Practical Considerations
Single-Shot vs Repeated Dosing: A large series of 4,014 patients demonstrated that single-shot Calafiore cardioplegia may be safe for procedures with shorter cross-clamp times, showing no difference in mortality, postoperative IABP use, or arrhythmias compared to repeated administration 3. However, repeated dosing showed lower rates of postoperative myocardial infarction.
Patient Selection: Blood cardioplegia solutions like Calafiore should be particularly considered in 1:
- Patients with anemia
- Low body surface area patients
- Chronic kidney disease
- Complex procedures requiring extended cross-clamp times
This preference is based on the need to minimize hemodilution, reduce bleeding complications, and decrease transfusion requirements.
Guideline Context
The 2019 EACTS/EACTA/EBCP guidelines emphasize that myocardial protection strategies should be patient-centered and tailored based on clinical condition and procedural complexity rather than relying on a fixed institutional solution 1. Blood cardioplegia (Class IIa, Level B recommendation) should be considered in selected patients to reduce hemodilution and transfusion requirements 1.
The 2021 AATS consensus document reinforces that blood cardioplegia is superior to crystalloid solutions, particularly in patients with ischemic cardiomyopathy where myocardial reserve is limited 4.